Molecular Therapy — Oncolytics · 2021 · 22 citations · 38 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCancer VaccinesT Cell Responses To TumorsTumor Immune MicroenvironmentVaccine-based ImmunotherapyAntigen-specific T Cell ResponsesCancer Vaccine ResponsesCancer Vaccine T-cell ResponsesCytotoxic T Lymphocyte InfiltrationIntratumoral AdministrationPd-l1 BlockadeProgrammed Cell Death Protein 1 (Pd-1) PathwayTumor Microenvironment Effects
The potency of cancer vaccines is often compromised by a variety of immunoinhibitory mechanisms, including stimulation of the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint pathway. Here, to overcome inhibition, we determined the potential of recombinant adeno-associated virus (rAAV)-vectored, PD1-based vaccination in the tumor microenvironment (TME) to activate antigen-specific T cell responses in the immune-competent murine mesothelioma model. We found that our rAAV-soluble PD1 (sPD1)-TWIST1 vaccine elicited and maintained TWIST1-specific cytotoxic T lymphocyte (CTL) responses and the PD-1 blocker systemically against lethal mesothelioma challenge after intramuscular injection, which was more effective than rAAV-TWIST1 or rAAV-sPD1 alone. More importantly, intratumoral injection of rAAV-sPD1-TWIST1 significantly enhanced immune surveillance by inducing TWIST1-specific CTL responses against vaccine-encoded TWIST1 and bystander gp70-AH1 epitopes, increasing CTL infiltration into the TME and decreasing tumor-associated immunosuppression, leading to complete elimination of established mesothelioma in 5 of 8 tumor-bearing mice. In addition, direct oncosuppression synergized with recruitment of T cells after localized rAAV-sPD1-TWIST1 treatment in a humanized mouse model to inhibit growth of REN human mesothelioma. Our results warrant clinical development of the rAAV-sPD1-TWIST1 vaccine to enhance immunotherapy against a wide range of TWIST1-expressing tumors.
38
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.9K citations
Medicine, Immunology, Oncology +17
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder, Vladimir Makarov, Taha Merghoub et al. · New England Journal of Medicine · 2014 · 4.4K citations · Full text
Medicine, Immunology, Oncology +17
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Jerry R. Mendell, Samiah Al-Zaidy, Richard Shell et al. · New England Journal of Medicine · 2017 · 2.3K citations · Full text
Jennifer Couzin-Frankel · Science · 2013 · 2K citations
Medicine, Immunology, Oncology +13